BC PharmaCare lists Maviret™ treatment for HCV

Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...

The Week in Review: Jan. 25, 2019 – Feb. 22, 2019

Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring

No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring Protocols?

Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV. HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca

The Week in Review: Jan. 18, 2019 – Jan. 25, 2019

Friday, Jan 25, 2019 News Recap: Using Telemedicine HCV Care Model in Prisons in SPAIN “HCV telemedicine program satisfying, cost-effective in Spanish prison:  A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model. Saturday in Surrey! Visit HepC

Using Nurse-led HCV Care Model in Prisons in AUSTRALIA

“Nurse-led HCV care model results in 95% or higher SVR rates in prison: A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study…” Read more... https://www.healio.com/hepatology/hepatitis-c/news/online/%7B33a10536-2c18-4632-9f19-995fafe9dd16%7D/nurse-led-hcv-care-model-results-in

Using Telemedicine HCV Care Model in Prisons in SPAIN

“HCV telemedicine program satisfying, cost-effective in Spanish prison:  A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more... https://www.healio.com/hepatology/hepatitis-c/news/online/%7b83ec8dfd-e12f-4288-9883-01a696c97dfa%7d/hcv-telemedicine-program-satisfying-cost-effective-in-spanish-prison...

Saturday in Surrey! Visit HepCBC booth at January 26th Surrey Health Expo

Come visit HepCBC’s “Liver Wellness” info table at the Surrey Health Expo on Saturday, January 26, 2019 between noon and 5 pm. It is at Surrey City Hall, 13450 – 104 Avenue in Surrey. Please stop by to say hello to our volunteers Dr. Anuradha Dhavan, Dr. Urvashi Beruar, and peer advocate Cheryl Reitz. View poster at: http://hepcbc.ca/wp-content/uploads/2019/01/20190126_SurreyHealthExpo.pdf View Hep CBC’s 2 page spread in South Asian Health magazine! The

Free CME-certified WEBINARS on Fatty Liver Disease Jan. 29-31, 2019

HepCBC is quite interested in NASH because people with hepatitis C are particularly vulnerable to NASH, even after being cured of hepatitis C!  (Reference for relation between post-SVR HCV and NASH: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859229/) Register for free CCO webinar: “Identifying and Managing NASH [Non-alcoholic steatohepatitis] in High-Risk Populations: A Silent Epidemic, NASH affects 30 million Americans, or 12% of all adults.  By 202

The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

CTAC Launches Campaign to End Hepatitis C in Canada

Elimination of infection in next 10 years possible through concerted action by policymakers and community leaders. TORONTO, Feb. 6, 2018 /CNW/ - The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to